Key Insights
The global Renal Denervation Devices Market is poised for significant expansion, with an estimated market size of $1253.4 million in 2025. This robust growth is fueled by a projected Compound Annual Growth Rate (CAGR) of 14.7% through 2033, indicating a dynamic and evolving landscape. The market's expansion is primarily driven by the increasing prevalence of hypertension and its associated cardiovascular complications, coupled with a growing awareness and adoption of minimally invasive treatment options. As healthcare systems worldwide grapple with the rising burden of lifestyle-related diseases, demand for effective and less invasive therapeutic modalities for managing resistant hypertension is escalating. This trend is further amplified by advancements in technology, leading to more sophisticated and targeted renal denervation systems that offer improved patient outcomes and reduced procedural complexities. The growing clinical evidence supporting the efficacy of renal denervation in lowering blood pressure is also a significant catalyst.
Renal Denervation Devices Market Market Size (In Billion)
The market is segmented by technology into Radiofrequency-based, Ultrasound-based, and Micro-infusion-based systems, each offering distinct advantages in treating renal artery sympathetic nerves. Key players such as Medtronic PLC, Abbott Laboratories, and Boston Scientific Corporation are at the forefront of innovation, investing heavily in research and development to refine existing technologies and introduce novel solutions. North America is expected to lead the market due to its advanced healthcare infrastructure and high adoption rate of new medical technologies, followed by Europe. The Asia Pacific region presents a substantial growth opportunity, driven by a growing patient pool, increasing disposable incomes, and a surge in healthcare expenditure. Despite the promising outlook, certain restraints, such as the need for further long-term clinical data and reimbursement challenges in some regions, need to be addressed to fully unlock the market's potential. However, the overarching trend points towards a rapidly expanding market for renal denervation devices as an integral part of managing complex cardiovascular conditions.
Renal Denervation Devices Market Company Market Share
This comprehensive report offers an in-depth analysis of the Renal Denervation Devices Market, a rapidly evolving sector crucial for managing resistant hypertension and cardiovascular health. Spanning from 2019 to 2033, with a base and estimated year of 2025 and a forecast period from 2025 to 2033, this study provides critical insights into market dynamics, competitive landscapes, and future trajectories. The report delves into historical data from 2019-2024, equipping stakeholders with a robust understanding of past performance and emerging trends.
This detailed report explores the Renal Denervation Devices Market, a critical area within interventional cardiology focused on treating patients with uncontrolled hypertension. The market is characterized by significant innovation, driven by the increasing prevalence of hypertension globally and the limitations of conventional pharmacological treatments for a substantial patient subset. This report leverages extensive research, encompassing historical data (2019-2024), a base year of 2025, and projections through 2033, offering a comprehensive outlook on the market's future.
Renal Denervation Devices Market Market Concentration & Innovation
The Renal Denervation Devices Market is characterized by a moderate level of market concentration, with key players like Medtronic PLC, Abbott Laboratories (St Jude Medical Inc), and Boston Scientific Corporation holding significant market shares. However, the landscape is dynamic, with ongoing innovation driving the entry of new technologies and the expansion of existing players. Innovation drivers include the pursuit of improved efficacy in blood pressure reduction, enhanced patient safety profiles, and the development of minimally invasive procedures. Regulatory frameworks, particularly those from the FDA and EMA, play a pivotal role in shaping product approvals and market access. Product substitutes, primarily pharmacological interventions, remain a competitive force, though the limitations of these treatments for refractory hypertension create a distinct market space for renal denervation. End-user trends highlight a growing demand for device-based solutions that offer sustained blood pressure control with fewer side effects. Mergers and acquisitions (M&A) activities are anticipated to increase as companies seek to consolidate their market positions and acquire novel technologies. The M&A deal value is projected to grow substantially as successful clinical trial data solidifies the therapeutic value of renal denervation.
- Market Share Dynamics: Leading companies like Medtronic PLC, Abbott Laboratories (St Jude Medical Inc), and Boston Scientific Corporation are key players.
- Innovation Drivers: Focus on enhanced efficacy, patient safety, and minimally invasive techniques.
- Regulatory Influence: FDA and EMA approvals are critical for market entry and expansion.
- Competitive Landscape: Pharmacological treatments remain a primary substitute, influencing market strategies.
- M&A Activities: Expected to rise, driven by technological advancements and market consolidation.
Renal Denervation Devices Market Industry Trends & Insights
The Renal Denervation Devices Market is poised for significant growth, driven by a confluence of compelling industry trends and insights. The escalating global prevalence of resistant hypertension, affecting millions of individuals worldwide, serves as a primary market growth driver. As pharmacological approaches reach their limitations for a considerable patient segment, the demand for effective, device-based interventional therapies like renal denervation is surging. Technological disruptions are at the forefront of this market's evolution, with continuous advancements in energy delivery systems and procedural techniques aiming to enhance efficacy and patient outcomes. Radiofrequency-based systems, initially dominant, are now complemented by emerging ultrasound-based and micro-infusion-based technologies, each offering distinct advantages in terms of tissue targeting and safety. Consumer preferences are increasingly leaning towards minimally invasive procedures that offer rapid recovery and long-term blood pressure management with reduced reliance on multiple medications and their associated side effects. The competitive dynamics within the renal denervation space are intensifying, with established medical device giants and innovative startups vying for market share. This competitive fervor fuels research and development, leading to the introduction of next-generation devices and expanding the therapeutic potential of renal denervation. The market penetration of renal denervation, while still in its nascent stages compared to more established interventional procedures, is expected to accelerate as pivotal clinical trial data, such as that from Medtronic's SPYRAL HTN program and ReCor Medical's RADIANCE-II trial, demonstrates clear benefits in achieving target blood pressure levels. These studies are pivotal in building clinician confidence and driving wider adoption. The projected Compound Annual Growth Rate (CAGR) for the renal denervation devices market is estimated to be robust, likely in the high teens, reflecting the unmet medical need and the growing body of clinical evidence supporting its efficacy. Key market penetration factors include physician education, reimbursement policies, and the successful navigation of regulatory pathways in different global regions. The shift towards value-based healthcare also favors therapies that can demonstrably improve patient outcomes and reduce long-term healthcare costs associated with poorly controlled hypertension.
Dominant Markets & Segments in Renal Denervation Devices Market
The Renal Denervation Devices Market exhibits distinct regional dominance and segment growth patterns, shaping its overall trajectory. North America, particularly the United States, currently stands as a dominant market due to its advanced healthcare infrastructure, high disposable income, and strong emphasis on technological innovation in medical devices. The presence of leading research institutions and a significant patient population with uncontrolled hypertension further solidifies its leadership.
Technology Segments Dominance:
Radiofrequency-based Technology: Historically, this segment has been the most dominant due to its earlier development and extensive clinical investigation.
- Key Drivers: Established track record, physician familiarity, and a growing body of evidence supporting its efficacy in reducing sympathetic nerve activity in the renal arteries. Significant investments in clinical trials by companies like Medtronic PLC have cemented its position. The availability of reimbursement for approved procedures in certain regions also contributes to its dominance.
- Dominance Analysis: RF-based systems have benefited from the initial wave of clinical research and regulatory approvals, making them the go-to option for many physicians and healthcare systems. The market size for this segment is substantial, driven by its early adoption.
Ultrasound-based Technology: This segment is rapidly gaining traction and is projected to witness significant growth, challenging the dominance of RF-based systems.
- Key Drivers: Ultrasound offers a non-thermal method of denervation, potentially reducing the risk of vascular injury and providing better selectivity. Companies like ReCor Medical Inc. (Otsuka Holdings Co Ltd) are making significant strides with their Paradise Ultrasound Renal Denervation (uRDN) System, as evidenced by the successful enrollment in their RADIANCE-II pivotal trial. The promise of a potentially safer and equally effective alternative is a major growth catalyst.
- Dominance Analysis: While currently smaller in market share than RF, ultrasound-based systems are capturing market attention due to their innovative approach and positive clinical trial outcomes. Their projected growth rate is expected to outpace that of RF in the coming years, driven by ongoing clinical validation and anticipated regulatory approvals.
Micro-infusion-based Technology: This emerging segment represents a novel approach to renal denervation, offering a more targeted and potentially less invasive method.
- Key Drivers: Micro-infusion systems aim to deliver ablative agents directly to the renal nerve branches, offering precise control and potentially minimizing off-target effects. Companies like Ablative Solutions Inc. are at the forefront of this technology. The appeal lies in its potential for procedural simplicity and tailored treatment.
- Dominance Analysis: This segment is in its early stages of development and market penetration. Its future dominance will depend on successful clinical validation, regulatory approvals, and demonstrating clear advantages over established technologies in terms of efficacy, safety, and cost-effectiveness.
The growth and dominance of these segments are intricately linked to economic policies that support medical device innovation and healthcare expenditure, along with the development of robust healthcare infrastructure capable of supporting these advanced interventional procedures.
Renal Denervation Devices Market Product Developments
Product innovation is the lifeblood of the Renal Denervation Devices Market. Companies are continuously refining their technologies to improve procedural efficiency, patient outcomes, and safety profiles. Key developments include advancements in energy delivery mechanisms, catheter design for better navigation within renal arteries, and the integration of real-time imaging and feedback systems. For instance, Medtronic PLC’s Symplicity Spyral Renal Denervation (RDN) system, highlighted by its recent clinical data, exemplifies the evolution towards more robust and well-documented therapeutic solutions. Competitive advantages are being forged through superior lesion creation, reduced procedure times, and demonstration of sustained blood pressure reduction in extensive clinical trials.
Report Scope & Segmentation Analysis
This report provides a granular analysis of the Renal Denervation Devices Market, segmented by technology to offer a detailed understanding of each segment's market dynamics.
Radiofrequency-based: This segment, historically dominant, continues to hold a significant market share due to established clinical data and physician familiarity. Its market size is substantial, driven by ongoing adoption in developed regions. Growth projections remain positive, though at a moderate pace compared to emerging technologies.
Ultrasound-based: This rapidly growing segment is characterized by innovative, non-thermal energy delivery. Driven by positive clinical trial outcomes and the promise of enhanced safety, this segment is expected to exhibit strong market penetration and significant growth in the coming years.
Micro-infusion-based: Representing a novel approach, this segment is in its early stages but holds considerable future potential. Its market size is currently smaller, but with dedicated research and development, it is poised for expansion as its efficacy and safety are further validated.
Key Drivers of Renal Denervation Devices Market Growth
The Renal Denervation Devices Market is propelled by several key drivers. The escalating global burden of hypertension, particularly resistant hypertension, creates a substantial unmet medical need. Technological advancements, such as the development of more precise and safer ablation techniques across RF, ultrasound, and micro-infusion modalities, are continuously improving treatment efficacy. Favorable regulatory pathways and increasing reimbursement availability in key markets are further incentivizing adoption. Moreover, growing awareness among healthcare professionals and patients regarding the benefits of interventional therapies for managing refractory hypertension significantly fuels market expansion.
Challenges in the Renal Denervation Devices Market Sector
Despite its promising outlook, the Renal Denervation Devices Market faces notable challenges. Rigorous and lengthy clinical trial processes are essential for regulatory approval and widespread adoption, posing significant time and financial investments. The perceived risk of complications, though diminishing with technological advancements, can still create hesitation among some clinicians. Intense competition from established pharmacological treatments and the ongoing development of novel drug therapies for hypertension present a persistent barrier. Furthermore, securing adequate reimbursement policies across diverse healthcare systems globally remains a critical hurdle for market access and expansion.
Emerging Opportunities in Renal Denervation Devices Market
Emerging opportunities within the Renal Denervation Devices Market are abundant. Expansion into emerging economies with a rising prevalence of hypertension and increasing healthcare expenditure presents a significant untapped market. The development of next-generation devices with enhanced targeting capabilities and integrated sensor technology for real-time monitoring offers avenues for improved patient care and outcomes. Furthermore, exploring new indications beyond resistant hypertension, such as sleep apnea and heart failure, could unlock substantial growth potential. Strategic partnerships and collaborations between device manufacturers, research institutions, and healthcare providers will be crucial in capitalizing on these opportunities.
Leading Players in the Renal Denervation Devices Market Market
- Symple Surgical
- Terumo Corporation
- Medtronic PLC
- Abbott Laboratories (St Jude Medical Inc )
- SoniVie
- Ablative Solutions Inc
- Otsuka Holdings Co Ltd (ReCor Medical Inc )
- Boston Scientific Corporation
- Mercator MedSystems
- Recor Medical Inc
Key Developments in Renal Denervation Devices Market Industry
- May 2022: Medtronic PLC released data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials.
- March 2022: ReCor Medical Inc., a fully owned subsidiary of Otsuka Medical Devices Co., Ltd, completed the enrollment in their RADIANCE-II pivotal trial of the Paradise Ultrasound Renal Denervation (uRDN) System for the treatment of uncontrolled hypertension.
Strategic Outlook for Renal Denervation Devices Market Market
The strategic outlook for the Renal Denervation Devices Market is overwhelmingly positive, driven by the sustained unmet need in managing resistant hypertension and the continuous innovation in therapeutic technologies. The market is poised for significant growth as robust clinical evidence solidifies the efficacy and safety of various renal denervation modalities, including radiofrequency, ultrasound, and micro-infusion-based systems. Strategic imperatives for market participants will involve continued investment in clinical research to generate further compelling data, securing favorable regulatory approvals, and navigating the complex reimbursement landscape. Expanding into new geographical markets, particularly those with a burgeoning hypertensive population and developing healthcare infrastructure, presents substantial growth catalysts. Furthermore, exploring synergistic applications of renal denervation beyond hypertension, such as in the treatment of sleep apnea or heart failure, will unlock new avenues for market expansion and solidify the long-term strategic importance of this therapeutic area.
Renal Denervation Devices Market Segmentation
-
1. Technology
- 1.1. Radiofrequency-based
- 1.2. Ultrasound-based
- 1.3. Micro-infusion-based
Renal Denervation Devices Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
- 4. Rest of the World
Renal Denervation Devices Market Regional Market Share
Geographic Coverage of Renal Denervation Devices Market
Renal Denervation Devices Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 14.7% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Prevalence of Hypertension; Long Lasting Effect of the Procedure
- 3.3. Market Restrains
- 3.3.1. Painful Procedure; Stringent Approval Process for Renal Denervation Devices and Reimbursement Systems
- 3.4. Market Trends
- 3.4.1. The Ultrasound-based Segment is Expected to be the Fastest-growing Segment Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Renal Denervation Devices Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Technology
- 5.1.1. Radiofrequency-based
- 5.1.2. Ultrasound-based
- 5.1.3. Micro-infusion-based
- 5.2. Market Analysis, Insights and Forecast - by Region
- 5.2.1. North America
- 5.2.2. Europe
- 5.2.3. Asia Pacific
- 5.2.4. Rest of the World
- 5.1. Market Analysis, Insights and Forecast - by Technology
- 6. North America Renal Denervation Devices Market Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Technology
- 6.1.1. Radiofrequency-based
- 6.1.2. Ultrasound-based
- 6.1.3. Micro-infusion-based
- 6.1. Market Analysis, Insights and Forecast - by Technology
- 7. Europe Renal Denervation Devices Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Technology
- 7.1.1. Radiofrequency-based
- 7.1.2. Ultrasound-based
- 7.1.3. Micro-infusion-based
- 7.1. Market Analysis, Insights and Forecast - by Technology
- 8. Asia Pacific Renal Denervation Devices Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Technology
- 8.1.1. Radiofrequency-based
- 8.1.2. Ultrasound-based
- 8.1.3. Micro-infusion-based
- 8.1. Market Analysis, Insights and Forecast - by Technology
- 9. Rest of the World Renal Denervation Devices Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Technology
- 9.1.1. Radiofrequency-based
- 9.1.2. Ultrasound-based
- 9.1.3. Micro-infusion-based
- 9.1. Market Analysis, Insights and Forecast - by Technology
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis 2025
- 10.2. Company Profiles
- 10.2.1 Symple Surgical
- 10.2.1.1. Overview
- 10.2.1.2. Products
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Financials (Based on Availability)
- 10.2.2 Terumo Corporation
- 10.2.2.1. Overview
- 10.2.2.2. Products
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Financials (Based on Availability)
- 10.2.3 Medtronic PLC
- 10.2.3.1. Overview
- 10.2.3.2. Products
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Financials (Based on Availability)
- 10.2.4 Abbott Laboratories (St Jude Medical Inc )
- 10.2.4.1. Overview
- 10.2.4.2. Products
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Financials (Based on Availability)
- 10.2.5 SoniVie
- 10.2.5.1. Overview
- 10.2.5.2. Products
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Financials (Based on Availability)
- 10.2.6 Ablative Solutions Inc
- 10.2.6.1. Overview
- 10.2.6.2. Products
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Financials (Based on Availability)
- 10.2.7 Otsuka Holdings Co Ltd (ReCor Medical Inc )
- 10.2.7.1. Overview
- 10.2.7.2. Products
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Financials (Based on Availability)
- 10.2.8 Boston Scientific Corporation
- 10.2.8.1. Overview
- 10.2.8.2. Products
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Financials (Based on Availability)
- 10.2.9 Mercator MedSystems
- 10.2.9.1. Overview
- 10.2.9.2. Products
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Financials (Based on Availability)
- 10.2.10 Recor Medical Inc
- 10.2.10.1. Overview
- 10.2.10.2. Products
- 10.2.10.3. SWOT Analysis
- 10.2.10.4. Recent Developments
- 10.2.10.5. Financials (Based on Availability)
- 10.2.1 Symple Surgical
List of Figures
- Figure 1: Global Renal Denervation Devices Market Revenue Breakdown (million, %) by Region 2025 & 2033
- Figure 2: Global Renal Denervation Devices Market Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Renal Denervation Devices Market Revenue (million), by Technology 2025 & 2033
- Figure 4: North America Renal Denervation Devices Market Volume (K Unit), by Technology 2025 & 2033
- Figure 5: North America Renal Denervation Devices Market Revenue Share (%), by Technology 2025 & 2033
- Figure 6: North America Renal Denervation Devices Market Volume Share (%), by Technology 2025 & 2033
- Figure 7: North America Renal Denervation Devices Market Revenue (million), by Country 2025 & 2033
- Figure 8: North America Renal Denervation Devices Market Volume (K Unit), by Country 2025 & 2033
- Figure 9: North America Renal Denervation Devices Market Revenue Share (%), by Country 2025 & 2033
- Figure 10: North America Renal Denervation Devices Market Volume Share (%), by Country 2025 & 2033
- Figure 11: Europe Renal Denervation Devices Market Revenue (million), by Technology 2025 & 2033
- Figure 12: Europe Renal Denervation Devices Market Volume (K Unit), by Technology 2025 & 2033
- Figure 13: Europe Renal Denervation Devices Market Revenue Share (%), by Technology 2025 & 2033
- Figure 14: Europe Renal Denervation Devices Market Volume Share (%), by Technology 2025 & 2033
- Figure 15: Europe Renal Denervation Devices Market Revenue (million), by Country 2025 & 2033
- Figure 16: Europe Renal Denervation Devices Market Volume (K Unit), by Country 2025 & 2033
- Figure 17: Europe Renal Denervation Devices Market Revenue Share (%), by Country 2025 & 2033
- Figure 18: Europe Renal Denervation Devices Market Volume Share (%), by Country 2025 & 2033
- Figure 19: Asia Pacific Renal Denervation Devices Market Revenue (million), by Technology 2025 & 2033
- Figure 20: Asia Pacific Renal Denervation Devices Market Volume (K Unit), by Technology 2025 & 2033
- Figure 21: Asia Pacific Renal Denervation Devices Market Revenue Share (%), by Technology 2025 & 2033
- Figure 22: Asia Pacific Renal Denervation Devices Market Volume Share (%), by Technology 2025 & 2033
- Figure 23: Asia Pacific Renal Denervation Devices Market Revenue (million), by Country 2025 & 2033
- Figure 24: Asia Pacific Renal Denervation Devices Market Volume (K Unit), by Country 2025 & 2033
- Figure 25: Asia Pacific Renal Denervation Devices Market Revenue Share (%), by Country 2025 & 2033
- Figure 26: Asia Pacific Renal Denervation Devices Market Volume Share (%), by Country 2025 & 2033
- Figure 27: Rest of the World Renal Denervation Devices Market Revenue (million), by Technology 2025 & 2033
- Figure 28: Rest of the World Renal Denervation Devices Market Volume (K Unit), by Technology 2025 & 2033
- Figure 29: Rest of the World Renal Denervation Devices Market Revenue Share (%), by Technology 2025 & 2033
- Figure 30: Rest of the World Renal Denervation Devices Market Volume Share (%), by Technology 2025 & 2033
- Figure 31: Rest of the World Renal Denervation Devices Market Revenue (million), by Country 2025 & 2033
- Figure 32: Rest of the World Renal Denervation Devices Market Volume (K Unit), by Country 2025 & 2033
- Figure 33: Rest of the World Renal Denervation Devices Market Revenue Share (%), by Country 2025 & 2033
- Figure 34: Rest of the World Renal Denervation Devices Market Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Renal Denervation Devices Market Revenue million Forecast, by Technology 2020 & 2033
- Table 2: Global Renal Denervation Devices Market Volume K Unit Forecast, by Technology 2020 & 2033
- Table 3: Global Renal Denervation Devices Market Revenue million Forecast, by Region 2020 & 2033
- Table 4: Global Renal Denervation Devices Market Volume K Unit Forecast, by Region 2020 & 2033
- Table 5: Global Renal Denervation Devices Market Revenue million Forecast, by Technology 2020 & 2033
- Table 6: Global Renal Denervation Devices Market Volume K Unit Forecast, by Technology 2020 & 2033
- Table 7: Global Renal Denervation Devices Market Revenue million Forecast, by Country 2020 & 2033
- Table 8: Global Renal Denervation Devices Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 9: United States Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 10: United States Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 11: Canada Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 12: Canada Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 13: Mexico Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 14: Mexico Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 15: Global Renal Denervation Devices Market Revenue million Forecast, by Technology 2020 & 2033
- Table 16: Global Renal Denervation Devices Market Volume K Unit Forecast, by Technology 2020 & 2033
- Table 17: Global Renal Denervation Devices Market Revenue million Forecast, by Country 2020 & 2033
- Table 18: Global Renal Denervation Devices Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 19: Germany Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 20: Germany Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 21: United Kingdom Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 22: United Kingdom Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 23: France Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 24: France Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 25: Italy Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 26: Italy Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 27: Spain Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 28: Spain Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 29: Rest of Europe Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 30: Rest of Europe Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 31: Global Renal Denervation Devices Market Revenue million Forecast, by Technology 2020 & 2033
- Table 32: Global Renal Denervation Devices Market Volume K Unit Forecast, by Technology 2020 & 2033
- Table 33: Global Renal Denervation Devices Market Revenue million Forecast, by Country 2020 & 2033
- Table 34: Global Renal Denervation Devices Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 35: China Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 36: China Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 37: Japan Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 38: Japan Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: India Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 40: India Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: Australia Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 42: Australia Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: South Korea Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 44: South Korea Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 45: Rest of Asia Pacific Renal Denervation Devices Market Revenue (million) Forecast, by Application 2020 & 2033
- Table 46: Rest of Asia Pacific Renal Denervation Devices Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 47: Global Renal Denervation Devices Market Revenue million Forecast, by Technology 2020 & 2033
- Table 48: Global Renal Denervation Devices Market Volume K Unit Forecast, by Technology 2020 & 2033
- Table 49: Global Renal Denervation Devices Market Revenue million Forecast, by Country 2020 & 2033
- Table 50: Global Renal Denervation Devices Market Volume K Unit Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Renal Denervation Devices Market?
The projected CAGR is approximately 14.7%.
2. Which companies are prominent players in the Renal Denervation Devices Market?
Key companies in the market include Symple Surgical, Terumo Corporation, Medtronic PLC, Abbott Laboratories (St Jude Medical Inc ), SoniVie, Ablative Solutions Inc, Otsuka Holdings Co Ltd (ReCor Medical Inc ), Boston Scientific Corporation, Mercator MedSystems, Recor Medical Inc.
3. What are the main segments of the Renal Denervation Devices Market?
The market segments include Technology.
4. Can you provide details about the market size?
The market size is estimated to be USD 1253.4 million as of 2022.
5. What are some drivers contributing to market growth?
Rising Prevalence of Hypertension; Long Lasting Effect of the Procedure.
6. What are the notable trends driving market growth?
The Ultrasound-based Segment is Expected to be the Fastest-growing Segment Over the Forecast Period.
7. Are there any restraints impacting market growth?
Painful Procedure; Stringent Approval Process for Renal Denervation Devices and Reimbursement Systems.
8. Can you provide examples of recent developments in the market?
May 2022: Medtronic PLC released data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Renal Denervation Devices Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Renal Denervation Devices Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Renal Denervation Devices Market?
To stay informed about further developments, trends, and reports in the Renal Denervation Devices Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
